SinoMab BioScience Limited (03681.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.0x

Market Cap

HKD 1.58B

MomentumView details →

1D Return

+0.88%

YTD Return

−14.18%

RSI (14)

47.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.0x

Market Cap

HKD 1.58B

RSI (14)

47.6

MomentumView details →

1D Return

+0.88%

YTD Return

−14.18%

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−5694.30%

EBITDA Margin

−4828.87%

ROE (TTM)

−90.22%

ROA (TTM)

−47.65%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−18.74%

EPS YoY

+41.99%

FCF YoY

+82.36%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+50.94%

EBITDA YoY

+35.08%

EarningsView details →

EPS (Actual)

−HKD 0.10

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.74x

Current Ratio

1.35x

Quick Ratio

1.35x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

5.73M

Net Income (TTM)

−326.11M

Op. CF (TTM)

—

Next earningsMar 22, 2027 →

Latest newsMore news →

China Antibody-B announced that Liang Fang resigned as executive director and chief operating officer, effective August 18, 2026, to devote more time to personal affairs.17d ago

Similar companies

HighTide Therapeutics Inc02511.HK NewAmsterdam Pharma Company N.V.NAMSW RAPT Therapeutics, Inc.RAPT Guangzhou Innogen Pharmaceutl Grp Co Ltd02591.HK LB Pharmaceuticals Inc Common StockLBRX Xeris Biopharma Holdings, Inc.XERS Find similar companies →

Latest newsMore news →

China Antibody-B announced that Liang Fang resigned as executive director and chief operating officer, effective August 18, 2026, to devote more time to personal affairs.17d ago